HK1151727A1 - Combination therapy with antibody drug conjugates - Google Patents
Combination therapy with antibody drug conjugatesInfo
- Publication number
- HK1151727A1 HK1151727A1 HK11105912.1A HK11105912A HK1151727A1 HK 1151727 A1 HK1151727 A1 HK 1151727A1 HK 11105912 A HK11105912 A HK 11105912A HK 1151727 A1 HK1151727 A1 HK 1151727A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- combination therapy
- drug conjugates
- antibody drug
- antibody
- conjugates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US97959407P | 2007-10-12 | 2007-10-12 | |
US2766808P | 2008-02-11 | 2008-02-11 | |
US4064108P | 2008-03-28 | 2008-03-28 | |
PCT/US2008/079224 WO2009048967A1 (en) | 2007-10-12 | 2008-10-08 | Combination therapy with antibody-drug conjugates |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1151727A1 true HK1151727A1 (en) | 2012-02-10 |
Family
ID=40549535
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK11105912.1A HK1151727A1 (en) | 2007-10-12 | 2011-06-10 | Combination therapy with antibody drug conjugates |
Country Status (14)
Country | Link |
---|---|
US (2) | US8263083B2 (ru) |
EP (1) | EP2211885B1 (ru) |
JP (1) | JP5485897B2 (ru) |
KR (1) | KR101641345B1 (ru) |
CN (1) | CN101969970B (ru) |
AU (1) | AU2008310908B2 (ru) |
CA (1) | CA2699090C (ru) |
EA (1) | EA020696B1 (ru) |
HK (1) | HK1151727A1 (ru) |
IL (1) | IL204851A (ru) |
MX (1) | MX2010003977A (ru) |
NZ (1) | NZ584552A (ru) |
WO (1) | WO2009048967A1 (ru) |
ZA (1) | ZA201002428B (ru) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG195524A1 (en) | 2003-11-06 | 2013-12-30 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugation to ligands |
US7750116B1 (en) * | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
ES2528922T3 (es) | 2007-07-16 | 2015-02-13 | Genentech, Inc. | Anticuerpos anti-CD79b humanizados e inmunoconjugados y métodos de uso |
TWI439286B (zh) | 2007-07-16 | 2014-06-01 | Genentech Inc | 抗-cd79b抗體及免疫共軛物及使用方法 |
KR101641345B1 (ko) | 2007-10-12 | 2016-07-20 | 시애틀 지네틱스, 인크. | 항체-약물 접합체를 이용한 병용 요법 |
MY157403A (en) | 2008-01-31 | 2016-06-15 | Genentech Inc | Anti-cd79b antibodies and immunoconjugates and methods of use |
CA3051090C (en) | 2009-01-09 | 2022-04-12 | Seattle Genetics, Inc. | Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates |
US8758758B1 (en) * | 2010-01-08 | 2014-06-24 | Seattle Genetics, Inc. | Post-relapse treatment of CD30 expressing lymphomas |
JP6046494B2 (ja) * | 2010-02-08 | 2016-12-14 | アジェンシス,インコーポレイテッド | 161p2f10bタンパク質に結合する抗体薬物コンジュゲート(adc) |
TW202344270A (zh) * | 2010-09-29 | 2023-11-16 | 美商艾澤西公司 | 與191p4d12蛋白結合之抗體藥物共軛物(adc) |
CA2815363C (en) | 2010-10-22 | 2020-07-14 | Seattle Genetics, Inc. | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mtor pathway |
EP2764351B1 (en) | 2011-09-29 | 2018-11-07 | Seattle Genetics, Inc. | Intact mass determination of protein conjugated agent compounds |
EA026643B1 (ru) | 2011-10-14 | 2017-04-28 | Сиэтл Дженетикс, Инк. | Пирролбензодиазепины и конъюгаты направленного действия |
SG11201401452PA (en) | 2011-11-17 | 2014-06-27 | Pfizer | Cytotoxic peptides and antibody drug conjugates thereof |
AU2013216863B2 (en) * | 2012-02-10 | 2018-09-06 | Seagen Inc. | Detection and treatment of CD30+ cancers |
EP2917240A1 (en) | 2012-11-07 | 2015-09-16 | Pfizer Inc. | Anti-notch3 antibodies and antibody-drug conjugates |
US9353150B2 (en) | 2012-12-04 | 2016-05-31 | Massachusetts Institute Of Technology | Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment |
ES2785551T3 (es) | 2014-06-30 | 2020-10-07 | Glykos Finland Oy | Derivado de sacárido de una carga útil tóxica y sus conjugados con anticuerpos |
PL3262071T3 (pl) | 2014-09-23 | 2020-08-10 | F. Hoffmann-La Roche Ag | Sposób stosowania immunokoniugatów anty-CD79b |
CN107148285B (zh) | 2014-11-25 | 2022-01-04 | Adc治疗股份有限公司 | 吡咯并苯并二氮杂䓬-抗体缀合物 |
WO2017197045A1 (en) | 2016-05-11 | 2017-11-16 | Movassaghi Mohammad | Convergent and enantioselective total synthesis of communesin analogs |
WO2018209239A1 (en) | 2017-05-11 | 2018-11-15 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
CA3078737A1 (en) * | 2017-10-11 | 2019-04-18 | Seattle Genetics, Inc. | Methods of reducing side effects of anti-cd30 antibody drug conjugate therapy |
JP2020536932A (ja) * | 2017-10-13 | 2020-12-17 | シアトル ジェネティクス インコーポレーテッド | 抗体−薬物コンジュゲートを用いた免疫応答の調節 |
US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
IL277748B1 (en) * | 2018-04-06 | 2024-03-01 | Seagen Inc | Camptothecin peptide conjugates |
BR112021012101A2 (pt) * | 2018-12-21 | 2021-09-08 | F. Hoffmann-La Roche Ag | Moléculas de ligação ao antígeno agonístico cd28 biespecífico, um ou mais polinucleotídeos isolados, um ou mais vetores, célula hospedeira, método de produção de uma molécula, composição farmacêutica, uso da molécula e método de inibição do crescimento de células tumorais |
US11535634B2 (en) | 2019-06-05 | 2022-12-27 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
CA3152316A1 (en) * | 2019-10-04 | 2021-04-08 | Scott C. Jeffrey | Camptothecin peptide conjugates |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5165922A (en) * | 1990-05-22 | 1992-11-24 | Bristol-Myers Squibb Company | Synergistic tumor therapy with combinations of biologically active anti-tumor antibodies and chemotherapy |
US6150508A (en) * | 1996-03-25 | 2000-11-21 | Northwest Biotherapeutics, Inc. | Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen |
US7090843B1 (en) * | 2000-11-28 | 2006-08-15 | Seattle Genetics, Inc. | Recombinant anti-CD30 antibodies and uses thereof |
US20040018194A1 (en) * | 2000-11-28 | 2004-01-29 | Francisco Joseph A. | Recombinant anti-CD30 antibodies and uses thereof |
EP1545613B9 (en) * | 2002-07-31 | 2012-01-25 | Seattle Genetics, Inc. | Auristatin conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
US20070134243A1 (en) * | 2004-12-01 | 2007-06-14 | Gazzard Lewis J | Antibody drug conjugates and methods |
WO2007011968A2 (en) * | 2005-07-18 | 2007-01-25 | Seattle Genetics, Inc. | Beta-glucuronide-linker drug conjugates |
US7973136B2 (en) * | 2005-10-06 | 2011-07-05 | Xencor, Inc. | Optimized anti-CD30 antibodies |
US7750116B1 (en) * | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
US8257706B2 (en) * | 2006-08-25 | 2012-09-04 | Seattle Genetics, Inc. | CD30 binding agents and uses thereof |
WO2008103916A2 (en) | 2007-02-23 | 2008-08-28 | The Trustees Of Columbia Univeristy In The City Of New York | Compositions and methods for treating cancer or a neurotrophic disorder |
KR101641345B1 (ko) | 2007-10-12 | 2016-07-20 | 시애틀 지네틱스, 인크. | 항체-약물 접합체를 이용한 병용 요법 |
-
2008
- 2008-10-08 KR KR1020107008660A patent/KR101641345B1/ko active IP Right Grant
- 2008-10-08 CA CA2699090A patent/CA2699090C/en active Active
- 2008-10-08 EA EA201070463A patent/EA020696B1/ru unknown
- 2008-10-08 AU AU2008310908A patent/AU2008310908B2/en active Active
- 2008-10-08 WO PCT/US2008/079224 patent/WO2009048967A1/en active Application Filing
- 2008-10-08 CN CN200880111297.1A patent/CN101969970B/zh active Active
- 2008-10-08 JP JP2010529007A patent/JP5485897B2/ja active Active
- 2008-10-08 US US12/681,599 patent/US8263083B2/en active Active
- 2008-10-08 NZ NZ584552A patent/NZ584552A/en unknown
- 2008-10-08 EP EP08837451.7A patent/EP2211885B1/en active Active
- 2008-10-08 MX MX2010003977A patent/MX2010003977A/es active IP Right Grant
-
2010
- 2010-04-06 IL IL204851A patent/IL204851A/en active IP Right Grant
- 2010-04-07 ZA ZA2010/02428A patent/ZA201002428B/en unknown
-
2011
- 2011-06-10 HK HK11105912.1A patent/HK1151727A1/xx unknown
-
2012
- 2012-08-13 US US13/571,313 patent/US8470329B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP5485897B2 (ja) | 2014-05-07 |
CA2699090C (en) | 2016-02-02 |
CN101969970B (zh) | 2014-10-15 |
US20100215671A1 (en) | 2010-08-26 |
ZA201002428B (en) | 2011-06-29 |
EP2211885B1 (en) | 2015-07-29 |
EP2211885A4 (en) | 2012-09-26 |
AU2008310908B2 (en) | 2014-01-09 |
IL204851A0 (en) | 2010-11-30 |
EA020696B1 (ru) | 2015-01-30 |
AU2008310908A1 (en) | 2009-04-16 |
WO2009048967A1 (en) | 2009-04-16 |
US8263083B2 (en) | 2012-09-11 |
NZ584552A (en) | 2012-07-27 |
CN101969970A (zh) | 2011-02-09 |
EP2211885A1 (en) | 2010-08-04 |
MX2010003977A (es) | 2010-04-30 |
KR20100087288A (ko) | 2010-08-04 |
CA2699090A1 (en) | 2009-04-16 |
KR101641345B1 (ko) | 2016-07-20 |
IL204851A (en) | 2016-08-31 |
US20130022627A1 (en) | 2013-01-24 |
US8470329B2 (en) | 2013-06-25 |
JP2011500582A (ja) | 2011-01-06 |
EA201070463A1 (ru) | 2010-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1151727A1 (en) | Combination therapy with antibody drug conjugates | |
HK1207976A1 (en) | Auristatin drug linker conjugates | |
EP1912671A4 (en) | BETA-glucuronide LINKER ARZNEIKONJUGATE | |
ZA201006763B (en) | Drug fusions and conjugates | |
ZA201001442B (en) | Combination therapy with type i and type ii anti-cd20 antibodies | |
EP2109625A4 (en) | USE OF ANTIBODY CONJUGATES | |
EP2253348A4 (en) | DEVICE FOR THE ADMINISTRATION OF MEDICINAL PRODUCTS | |
EP2190853A4 (en) | HALOGENIDE-FREE COMPLEXES FROM GLUCOSAMINE AND AN ACIDIC ACID | |
IL197316A0 (en) | Buprenophine-wafer for drug substitution therapy | |
ZA201201218B (en) | 3-polylysine conjugates and the use thereof | |
IL199992A0 (en) | Combination therapy | |
EP1841467A4 (en) | COMBINATION CANCER THERAPY WITH ANTI-PSMA ANTIBODIES | |
EP2054061A4 (en) | COMBINATION THERAPY | |
ZA200806318B (en) | Drug combinations | |
GB0719518D0 (en) | Therapy | |
ZA201003729B (en) | Conjugates of anti-rg-1 antibodies | |
GB0815788D0 (en) | Therapeutic antibodies | |
EP1838317A4 (en) | ANALGESIC CONJUGATES | |
IL197883A0 (en) | Combination drug | |
GB0700773D0 (en) | Drug therapies | |
EP2076239A4 (en) | COMBINATION THERAPY | |
GB0600528D0 (en) | Drug detector | |
EP2211863A4 (en) | COMBINATION THERAPY | |
IL199718A0 (en) | Peptide-complement conjugates | |
EP2324059A4 (en) | THERAPEUTIC ANTI-PAMP ANTIBODIES |